Abstract
The application discloses selective ACKR3 modulating peptides comprising amino acid sequence FGGX1MRRX2 (SEQ ID NO: 1), wherein X1 is F or W; X2 is K, V or F; and wherein the peptides have a length of at most 15 amino acids; fusion proteins comprising the peptides as taught herein; nucleic acids encoding the peptides as taught herein; nucleic acid expression cassettes and vectors comprising the nucleic acid as taught herein; and pharmaceutical compositions comprising the peptide as taught herein or the nucleic acid as taught herein. Further provided are the peptide as taught herein for use as a medicament; methods for in vitro or ex vivo diagnosis, prediction, prognosis and/or monitoring of a disease or condition characterized by an aberrant level of ACKR3 polypeptide using the peptide as taught herein; and in vitro methods for identifying an agent useful as a therapeutic using the peptide as taught herein.
Original language | English |
---|---|
Patent number | WO 2020/225070A1 |
IPC | A61K38/00; A61K47/62; A61K47/64; A61K48/00; C07K7/08; C12N15/86; G01N33/58 |
Priority date | 3/05/19 |
Filing date | 30/04/20 |
Publication status | Published - 12 Nov 2020 |